Sunday, March 3, 2024
Home » Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg

Zydus receives final approval from the USFDA for Darunavir Tablets 600 mg and 800 mg

by Koushik Gope
0 comment

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Darunavir Tablets 600 mg and 800 mg, and tentative approval for 75 mg and 150 mg tablets (USRLD: Prezista® Tablets, 75 mg, 150 mg, 600 mg, and 800 mg).

Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body.

It is indicated for the treatment of HIV-1 infection in adult patients. It is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. It must be –co-administered with Ritonavir and with other antiretroviral agents. The product will be manufactured at the group’s formulation manufacturing facility in SEZ, Ahmedabad (India).

Darunavir Tablets, 75 mg, 150 mg, 600 mg, and 800 mg had annual sales of USD 275 mn in the United States (IQVIA MAT Oct. 2023).

The group now has 383 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.

You may also like

Leave a Comment

Welcome to the world of ISMDU, here we help you stay up-to-date on the latest market trends and news from around the world. Our mission is simple: to educate our readers about what’s happening in the stock market, so they can be prepared when opportunities arise.

© 2023 ISMDU • Designed by Dimagital Media